{"id":581180,"date":"2026-04-04T06:31:29","date_gmt":"2026-04-04T06:31:29","guid":{"rendered":"https:\/\/www.newsbeep.com\/ca\/581180\/"},"modified":"2026-04-04T06:31:29","modified_gmt":"2026-04-04T06:31:29","slug":"glp-1-drugs-can-cause-pancreatitis-kidney-injury-bowel-obstruction-ministry-warns-the-south-first","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/ca\/581180\/","title":{"rendered":"GLP-1 drugs can cause pancreatitis, kidney injury, bowel obstruction, ministry warns – The South First"},"content":{"rendered":"

In India, GLP-1 drugs can only be prescribed by endocrinologists, internal medicine specialists, and cardiologists. The drugs cannot be purchased over the counter.
\n \"\"<\/p>\n

Published Apr 01, 2026 | 2:28 PM \u268a Updated Apr 01, 2026 | 2:29 PM<\/p>\n


\n \"subscribe\"\/
\n <\/a>
\n Share<\/p>\n

\"GLP-1<\/p>\n

GLP-1 drugs. (iStock)<\/p>\n

Synopsis: Government releases guidance on 1 April as generic versions flood market, prices fall 85 percent. Drugs require specialist prescription. \u201cGLP-1 drugs are prescription medications used to treat type 2 diabetes and obesity but carry serious side effects and must only be taken under the supervision of a qualified medical specialist,\u201d the ministry stated. \u201cThe misuse of GLP-1 drugs without clinical oversight can lead to severe health complications.\u201d<\/p>\n

GLP-1 receptor agonist drugs carry serious side effects ranging from nausea and vomiting to pancreatitis, acute kidney injury, bowel obstruction, and medullary thyroid cancer, the Ministry of Health and Family Welfare warned on 1 April, 2026.<\/p>\n

The ministry released comprehensive guidance on the prescription-only medications as at least six domestic pharmaceutical companies flooded the market with generic versions following patent expiry on 20 March. Monthly treatment costs fell overnight from \u20b98,800-\u20b910,850 to as low as \u20b91,300.<\/p>\n

\u201cGLP-1 drugs are prescription medications used to treat type 2 diabetes and obesity but carry serious side effects and must only be taken under the supervision of a qualified medical specialist,\u201d the ministry stated. \u201cThe misuse of GLP-1 drugs without clinical oversight can lead to severe health complications.\u201d<\/p>\n

Also Read:\u00a0Generic Semaglutide launches in India after patent expiry<\/a>
\nSide effects range from mild to severe<\/p>\n

Common side effects include nausea, vomiting, diarrhea, constipation, and loss of appetite. These typically occur during early treatment as the body adjusts to the medication.<\/p>\n

Severe and rare side effects requiring emergency medical attention include:<\/p>\n

Pancreatitis: Inflammation of the pancreas causing severe abdominal pain.
\nMedullary thyroid cancer: Rare thyroid cancer linked to GLP-1 use in animal studies.
\nAcute kidney injury: Sudden kidney failure, particularly in patients who become dehydrated from gastrointestinal side effects.
\nWorsening diabetic retinopathy: Rapid improvement in blood sugar can temporarily worsen eye damage in diabetic patients.
\nGastroparesis: Slowed or stopped stomach emptying causing persistent nausea and vomiting.
\nBowel obstruction: Blockage in the intestines requiring immediate medical intervention.
\nGallstone attacks and bile duct blockage: Rapid weight loss increases risk of gallbladder complications.<\/p>\n

\"\"<\/a><\/p>\n

Side effects of GLP1<\/p>\n

The drugs may also cause severe allergic reactions including shortness of breath, red rash, hives, abdominal pain, difficulty swallowing, and chest tightness.<\/p>\n

Low blood sugar can occur when GLP-1 drugs are combined with other diabetes medications, causing shaking, sweating, dizziness, weakness, faster heart rate, and difficulty thinking.<\/p>\n

The drugs are contraindicated in pregnant women due to risk of developmental abnormalities in the foetus. They are also contraindicated in those with personal or family history of medullary thyroid carcinoma and those with multiple endocrine neoplasia type 2.<\/p>\n

Prescription restrictions<\/p>\n

In India, GLP-1 drugs can only be prescribed by endocrinologists, internal medicine specialists, and cardiologists. The drugs cannot be purchased over the counter. \u201cGLP-1 drugs must be taken under medical supervision,\u201d the ministry emphasized.<\/p>\n

\u201cGLP-1 drugs are prescription medications used to treat type 2 diabetes and obesity but carry serious side effects and must only be taken under the supervision of a qualified medical specialist,\u201d the ministry stated.<\/p>\n

The drugs work by mimicking GLP-1, a hormone the gut releases after eating that stimulates insulin release and suppresses glucagon to control blood sugar. They also slow gastric emptying, creating prolonged fullness that reduces appetite and induces weight loss.<\/p>\n

Also Read:\u00a0GLP-1 drugs going generic: What it means \u2014 cost, access and caution<\/a>
\nInspection and enforcement actions<\/p>\n

The Drug Controller General of India, in collaboration with State Drug Controllers, audited and inspected 49 businesses across the country in recent weeks. Inspections covered online pharmacy warehouses, drug wholesalers, retailers, and weight loss clinics.<\/p>\n

\u201cThese inspections spanned multiple regions across India and focused on identifying violations related to unauthorised sale, improper prescription practices, and misleading marketing,\u201d stated an official release. \u201cNotices have been issued to those found breaking the rules.\u201d<\/p>\n

Businesses that violate regulations will face license cancellation, fines, and legal action. Stricter inspections will continue in coming weeks.<\/p>\n

Generic market entry<\/p>\n

On 21 March, Dr Reddy\u2019s, Sun Pharma, Zydus Lifesciences, Glenmark, Alkem, and Natco launched generic semaglutide formulations. Some formats undercut the innovator price by up to 90 percent.<\/p>\n

For a country with over 10 crore adults living with diabetes and an estimated 25 crore with obesity, the price reduction represents a significant accessibility shift, creating both opportunity and risk. Analysts project the market could expand fivefold within five years.<\/p>\n

However, increased accessibility has raised concerns about misuse without clinical oversight.<\/p>\n

Meanwhile, multiple variants have also entered the market, including semaglutide injection, semaglutide tablets, liraglutide, tirzepatide, dulaglutide, exenatide, and exenatide extended release. Most are administered via pre-filled injection pens, though some are available in tablet form.<\/p>\n

The first GLP-1 medication received approval from the United States Food and Drug Administration in 2005. Recent variants have gained popularity for treating both diabetic and obese patients.<\/p>\n

Indian BMI thresholds differ from Western standards<\/p>\n

For Indian populations, obesity is defined as BMI greater than or equal to 25 kg\/m\u00b2, while overweight ranges from 23.00 to 24.99 kg\/m\u00b2. These thresholds are lower than Western standards due to higher cardiometabolic risk at lower body mass index levels in South Asian populations.<\/p>\n

GLP-1 drugs are indicated for patients with BMI above 25 even without complications, or BMI above 23 with obesity-related conditions such as diabetes, hypertension, or fatty liver disease.<\/p>\n

The ministry, however, emphasized that type 2 diabetes and obesity remain preventable and reversible conditions.<\/p>\n

To prevent type 2 diabetes, people should reach and maintain healthy body weight, engage in at least 150 minutes of moderate exercise each week, eat a healthy diet avoiding sugar and saturated fats, and not smoke tobacco.<\/p>\n

To prevent and reduce obesity, people should reduce calories consumed from fats and sugars, increase daily intake of fruit, vegetables, legumes, whole grains and nuts, and engage in regular physical activity.<\/p>\n

\u201cPharmaceutical therapy, where indicated, must not be projected in a manner that undermines public health initiatives promoting diet control, physical activity, and preventive healthcare measures,\u201d the DCGI advisory stated.<\/p>\n

Action against misleading ads<\/p>\n

On 10 March, 2026, the DCGI issued a comprehensive advisory to all drug manufacturers ordering them to stop misleading advertisements and any promotion that could encourage people to use GLP-1 drugs without prescription.<\/p>\n

The advisory specifically prohibits surrogate advertising disguised as disease awareness campaigns, including billboards at shopping centers, pharmacy signboards advertising availability, social media influencer endorsements, and digital campaigns that create brand recall for prescription products.<\/p>\n

\u201cAny promotional activity, including so-called awareness campaigns, that functions as a surrogate advertisement for prescription-only drugs shall be viewed seriously and may be treated as irrational or misleading marketing practice,\u201d stated Dr Rajeev Singh Raghuvanshi, Drugs Controller General of India.<\/p>\n

Also Read:\u00a0Awareness or surrogate advertising? CDSCO flags GLP-1 obesity campaigns<\/a>
\nCompliance requirements<\/p>\n

The ministry further requires all manufacturers, importers, and marketing authorization holders to ensure strict compliance with the Drugs and Cosmetics Act, 1940 and Rules made thereunder.<\/p>\n

Product information leaflets must prominently display details of authorized personnel, authorized office codes, and dedicated contact numbers with complaint mechanisms for addressing consumer queries.<\/p>\n

Firms must submit comprehensive risk management plans ensuring continued safety monitoring and implementation of appropriate risk minimization measures.<\/p>\n

Public advisory<\/p>\n

Patients and the public are strongly advised to consult qualified medical specialists before use and obtain these medications with prescription only through legitimate, regulated channels.<\/p>\n

The ministry warned against purchasing GLP-1 drugs from unauthorized sources, using them without medical supervision, or taking them for cosmetic weight loss purposes.<\/p>\n

\u201cIndia\u2019s regulatory authorities have taken firm steps to prevent unsupervised use and malpractices in the supply chain,\u201d the release stated. \u201cThese drugs are not without risk.\u201d<\/p>\n

The Drug Controller General of India continues to monitor the situation closely as the market expands following generic entry.<\/p>\n

Also Read:\u00a0GLP-1 drugs move beyond diabetes and weight loss to multi-organ protection<\/a><\/p>\n

(Edited by Sumavarsha)<\/p>\n

\"journalist-ad\"<\/p>\n","protected":false},"excerpt":{"rendered":"In India, GLP-1 drugs can only be prescribed by endocrinologists, internal medicine specialists, and cardiologists. The drugs cannot…\n","protected":false},"author":2,"featured_media":581181,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[33],"tags":[49,48,84,377],"class_list":{"0":"post-581180","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-medication","8":"tag-ca","9":"tag-canada","10":"tag-health","11":"tag-medication"},"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/posts\/581180","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/comments?post=581180"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/posts\/581180\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/media\/581181"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/media?parent=581180"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/categories?post=581180"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/tags?post=581180"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}